VRT-18858
VRT-18858 (RU-36384), the active metabolite of Pralnacasan (HY-19676), is a potent interleukin-1β converting enzyme (ICE) inhibitor (Ki = 1.4 nM). VRT-18858 inhibits LPS (HY-D1056)-induced IL-1β release (IC50 = 0.42 µM) and S. aureus Cowan-induced IL-1β and IL-18 release (IC50=1.3 and 2.1 µM, respectively) in human peripheral blood mononuclear cells. VRT-18858 can be used for osteoarthritis research.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- CAS 番号: 192756-07-3
- 分子式: C24H25N5O7
- 分子量:495.48
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
生物活性
製品説明
IC50 & Target
[1]|
IL-1β |
IL-18 |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| PBMC | IC50 |
0.38 μM
Compound: 2a
|
Inhibition of LPS-induced IL1-beta production in human PBMC by ELISA
Inhibition of LPS-induced IL1-beta production in human PBMC by ELISA
|
[PMID: 20656488] |
| PBMC | IC50 |
0.85 μM
Compound: VRT-18858
|
Inhibition of LPS-induced IL-1beta release in PBMC (unknown origin)
Inhibition of LPS-induced IL-1beta release in PBMC (unknown origin)
|
[PMID: 34823899] |
化学情報
-
CAS 番号 192756-07-3
-
分子量 495.48
-
分子式 C24H25N5O7
-
SMILES
O=C([C@@H](NC(C1=NC=CC2=C1C=CC=C2)=O)CC3)N([C@H](C(N[C@H](C=O)CC(O)=O)=O)CCC4)N4C3=O
-
別名
RU-36384
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
プロトコル
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
PBMC Thawing for Immune Assays
PBMC thawing for immune assays recovers viable cryopreserved peripheral blood mononuclear cells for downstream functional or phenotypic readouts, including ELISPOT, intracellular cytokine staining, proliferation assays, and flow-cytometric immunophenotyping. Cryopreserved PBMCs can support immune monitoring because antigen-specific T-cell function and major CD4/CD8 phenotypes may be retained after optimized freezing and thawing, although some lymphocyte subsets and activation or memory markers can be altered by cryopreservation. The technical objective is rapid warming of the frozen vial followed by controlled dilution and removal of DMSO-containing cryomedium, because thawing and wash conditions measurably affect viable PBMC recovery and downstream assay performance. Viability alone is insufficient for protocol evaluation because high viability may occur with low live-cell recovery, so both viable percentage and absolute live-cell recovery should be measured after thawing.
-
Pyroptosis Solutions
Pyroptosis is a lytic inflammatory cell-death pathway executed by gasdermin pores, most classically through inflammasome-mediated activation of caspase-1, cleavage of gasdermin D, membrane pore formation, LDH release, and secretion of IL-1β and IL-18. The canonical pathway is commonly modeled by priming cells with an inflammatory signal such as LPS to induce pro-IL-1β and inflammasome components, followed by an activation signal such as ATP or nigericin to activate NLRP3, ASC speck formation, caspase-1 cleavage, GSDMD cleavage, cytokine release, and pyroptotic membrane rupture. The non-canonical pathway is triggered when cytosolic LPS activates mouse caspase-11 or human caspase-4/5, leading to GSDMD cleavage and pyroptosis, and this can secondarily activate NLRP3-dependent IL-1β release. Pyroptosis is linked to inflammatory injury, infection, cancer, liver disease, ocular disease, placental inflammation, and other disease phenotypes, but unresolved questions include which gasdermin fam
純度とドキュメンテーション
参考文献
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)